期刊
CYTOKINE & GROWTH FACTOR REVIEWS
卷 22, 期 2, 页码 99-108出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.cytogfr.2011.04.001
关键词
Interleukin 15; Tumor therapy; Cancer; Cytokines
资金
- Foundation for Polish Science
- EU
- European Regional Development Fund [POIG.01.01.02-00-008/08]
Interleukin 15 participates in the development of important immune antitumor mechanisms. It activates CD8(+)T cells, natural killer (NK) cells, NK T cells, and can promote the formation of antitumor antibodies. IL-15 can also protect T effector cells from the action of T regulatory cells and reverse tolerance to tumor-associated antigens. In pre-clinical studies IL-15 has been found to demonstrate potentiated antitumor effects following pre-association with IL-15Ra, or when used in combination with chemotherapy, adoptive therapy, monoclonal antibodies, and tumor vaccines. Although a clinical trial based on application of IL-15 in tumor patients has already begun, it is important to be aware of its potential side effects, including induction of autoimmunity and promotion of proliferation, survival, and dissemination of some tumor cells. (C) 2011 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据